Propanc Biopharma Files 8-K/A Amendment
Ticker: PPCB · Form: 8-K/A · Filed: Jun 13, 2024 · CIK: 1517681
| Field | Detail |
|---|---|
| Company | Propanc Biopharma, Inc. (PPCB) |
| Form Type | 8-K/A |
| Filed Date | Jun 13, 2024 |
| Risk Level | medium |
| Pages | 3 |
| Reading Time | 3 min |
| Key Dollar Amounts | $20,000, $100,000 |
| Sentiment | neutral |
Sentiment: neutral
Topics: amendment, material-agreement, equity-sale
TL;DR
Propanc Biopharma filed an 8-K/A amendment on June 13, 2024, updating details on material agreements and equity sales.
AI Summary
Propanc Biopharma, Inc. filed an amendment (8-K/A) on June 13, 2024, to a previous filing concerning events on June 3, 2024. The amendment relates to the entry into a material definitive agreement, the creation of a direct financial obligation, and unregistered sales of equity securities.
Why It Matters
This amendment provides updated or corrected information regarding significant financial and contractual events for Propanc Biopharma, Inc., which could impact investors' understanding of the company's financial obligations and equity structure.
Risk Assessment
Risk Level: medium — Amendments to 8-K filings often indicate a need for clarification or correction of previously disclosed material events, which can introduce uncertainty.
Key Players & Entities
- Propanc Biopharma, Inc. (company) — Registrant
- June 3, 2024 (date) — Earliest event date reported
- June 13, 2024 (date) — Filing date of the amendment
FAQ
What specific material definitive agreement is being amended or clarified in this 8-K/A filing?
The filing indicates an amendment related to the entry into a material definitive agreement, but the specific details of the agreement are not provided in the provided text.
What type of direct financial obligation was created or is being reported on?
The filing states the creation of a direct financial obligation or an obligation under an off-balance sheet arrangement, but the nature of this obligation is not detailed in the provided text.
What were the circumstances of the unregistered sales of equity securities mentioned?
The filing lists 'Unregistered Sales of Equity Securities' as an item information, but the specifics of these sales are not detailed in the provided text.
Why is Propanc Biopharma, Inc. filing an amendment (8-K/A) instead of a standard 8-K?
An 8-K/A is filed to amend or correct information previously reported in a Form 8-K, indicating that the original filing may have contained inaccuracies or omissions.
What is the significance of the 'Date as of Change' being June 3, 2024?
The 'Date as of Change' of June 3, 2024, indicates the date on which the earliest reported event, which is being amended or clarified, occurred.
Filing Stats: 754 words · 3 min read · ~3 pages · Grade level 10.9 · Accepted 2024-06-13 06:10:48
Key Financial Figures
- $20,000 — ompany an aggregate principal amount of $20,000 AUD. The Company intends to use the net
- $100,000 — ompany an aggregate principal amount of $100,000 AUD. The Company intends to use the net
Filing Documents
- form8-ka.htm (8-K/A) — 41KB
- ex4-1.htm (EX-4.1) — 13KB
- ex4-2.htm (EX-4.2) — 14KB
- ex4-1_001.jpg (GRAPHIC) — 4KB
- ex4-1_002.jpg (GRAPHIC) — 3KB
- ex4-1_003.jpg (GRAPHIC) — 2KB
- ex4-1_004.jpg (GRAPHIC) — 3KB
- ex4-2_001.jpg (GRAPHIC) — 5KB
- ex4-2_002.jpg (GRAPHIC) — 3KB
- ex4-2_003.jpg (GRAPHIC) — 2KB
- ex4-2_004.jpg (GRAPHIC) — 2KB
- 0001493152-24-023626.txt ( ) — 273KB
- ppcb-20240603.xsd (EX-101.SCH) — 3KB
- ppcb-20240603_lab.xml (EX-101.LAB) — 33KB
- ppcb-20240603_pre.xml (EX-101.PRE) — 22KB
- form8-ka_htm.xml (XML) — 3KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: June 11, 2024 PROPANC BIOPHARMA, INC. By: /s/ James Nathanielsz Name: James Nathanielsz Title: Chief Executive Officer and Chief Financial Officer